CITIUS PHARMAC Cash And Equivalents vs. Total Debt
| 47N Stock | EUR 3.29 0.00 0.00% |
For CITIUS PHARMAC profitability analysis, we use financial ratios and fundamental drivers that measure the ability of CITIUS PHARMAC to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well CITIUS PHARMAC DL utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between CITIUS PHARMAC's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of CITIUS PHARMAC DL over time as well as its relative position and ranking within its peers.
CITIUS |
CITIUS PHARMAC DL Total Debt vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining CITIUS PHARMAC's current stock value. Our valuation model uses many indicators to compare CITIUS PHARMAC value to that of its competitors to determine the firm's financial worth. CITIUS PHARMAC DL is number one stock in cash and equivalents category among its peers. It is rated second in total debt category among its peers making up about 0.01 of Total Debt per Cash And Equivalents. The ratio of Cash And Equivalents to Total Debt for CITIUS PHARMAC DL is roughly 109.11 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CITIUS PHARMAC's earnings, one of the primary drivers of an investment's value.CITIUS Total Debt vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
CITIUS PHARMAC |
| = | 115.66 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
CITIUS PHARMAC |
| = | 1.06 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CITIUS Total Debt vs Competition
CITIUS PHARMAC DL is rated second in total debt category among its peers. Total debt of Biotechnology industry is presently estimated at about 1.12 Billion. CITIUS PHARMAC adds roughly 1.06 Million in total debt claiming only tiny portion of stocks in Biotechnology industry.
CITIUS PHARMAC Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in CITIUS PHARMAC, profitability is also one of the essential criteria for including it into their portfolios because, without profit, CITIUS PHARMAC will eventually generate negative long term returns. The profitability progress is the general direction of CITIUS PHARMAC's change in net profit over the period of time. It can combine multiple indicators of CITIUS PHARMAC, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products targeting medical needs with a focus on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. CITIUS PHARMAC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 10 people.
CITIUS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on CITIUS PHARMAC. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of CITIUS PHARMAC position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the CITIUS PHARMAC's important profitability drivers and their relationship over time.
Use CITIUS PHARMAC in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CITIUS PHARMAC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CITIUS PHARMAC will appreciate offsetting losses from the drop in the long position's value.CITIUS PHARMAC Pair Trading
CITIUS PHARMAC DL Pair Trading Analysis
The ability to find closely correlated positions to CITIUS PHARMAC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CITIUS PHARMAC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CITIUS PHARMAC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CITIUS PHARMAC DL to buy it.
The correlation of CITIUS PHARMAC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CITIUS PHARMAC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CITIUS PHARMAC DL moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CITIUS PHARMAC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your CITIUS PHARMAC position
In addition to having CITIUS PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in CITIUS Stock
To fully project CITIUS PHARMAC's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of CITIUS PHARMAC DL at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include CITIUS PHARMAC's income statement, its balance sheet, and the statement of cash flows.